FDA/EMA drug approval probability + PDUFA calendar for a disease area — which Phase 3 drug
FDA/EMA drug approval probability + PDUFA calendar for a disease area — which Phase 3 drugs are most likely to win approval in 12-24 months, with mechanism, trial results, approval-probability scores and historical phase-3 success rates. Worldwide. For biotech-investing and payer agents.
250000 (raw units)
price
1
calls / 30d
1
unique payers
2026-08-20
updated
Provider
clinicalintelpulse.theaslangroupllc.com · discovered, not yet claimed by its owner
Payment (x402 accepts[])
[
{
"scheme": "exact",
"network": "eip155:8453",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913",
"amount": "250000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:8453",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913",
"amount": "250000",
"maxTimeoutSeconds": 604900
},
{
"scheme": "exact",
"network": "solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp",
"payTo": "985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1",
"asset": "EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v",
"amount": "250000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:137",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x3c499c542cEF5E3811e1192ce70d8cC03d5c3359",
"amount": "250000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:42161",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0xaf88d065e77c8cC2239327C5EDb3A432268e5831",
"amount": "250000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:480",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x79A02482A880bCe3F13E09da970dC34dB4cD24D1",
"amount": "250000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:143",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x754704Bc059F8C67012fEd69BC8A327a5aafb603",
"amount": "250000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:196",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x779ded0c9e1022225f8e0630b35a9b54be713736",
"amount": "250000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:999",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0xb88339CB7199b77E23DB6E890353E22632Ba630f",
"amount": "250000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k",
"payTo": "62A253YPATFNJCPRKID3FKD77MYJFNTVRYRP4B4JWG36EGLPY7UXFWGI7I",
"asset": "31566704",
"amount": "250000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "xrpl:0",
"payTo": "rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32",
"asset": "XRP",
"amount": "250000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "xrpl:0",
"payTo": "rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32",
"asset": "524C555344000000000000000000000000000000",
"amount": "0.25",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:56",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x8d0D000Ee44948FC98c9B98A4FA4921476f08B0d",
"amount": "250000000000000000",
"maxTimeoutSeconds": 300
}
]Output schema
{
"bazaar": {
"info": {
"input": {
"method": "GET",
"queryParams": {
"agency": "FDA | EMA | both (default: both)",
"condition": "Disease area — e.g. \"Alzheimer Disease\" | \"Multiple Myeloma\" | \"NASH\" | \"Heart Failure\" | \"Obesity\"",
"horizon": "12m | 18m | 24m (default: 18m)",
"lang": "en | es | fr | de | ja | zh | ko | pt | ar | hi (default: en)"
},
"type": "http"
},
"output": {
"example": {
"approval_candidates": [
{
"approval_probability": 85,
"drug": "Lecanemab (Leqembi)",
"ema_status": "CHMP assessment ongoing 2025",
"fda_status": "Full approval received 2023; expanded label applications pending",
"key_risk": "ARIA (amyloid-related imaging abnormalities) safety profile limiting real-world use",
"mechanism": "Anti-amyloid monoclonal antibody (protofibrils)",
"nctId": "NCT03887455",
"sponsor": "Eisai / Biogen",
"trial_result": "Positive — 27% slowing of clinical decline vs placebo (p<0.001)"
}
],
"approval_rate_context": {
"disease_area_historical_phase3_success_pct": 55,
"rare_disease_premium": "Breakthrough therapy designation adds ~15% probability uplift",
"us_approval_rate_phase3_pct": 58
},
"market_context": "Alzheimer's is the highest-value CNS approval category. Any successful amyloid or tau therapy represents $5-15B peak sales potential.",
"pdufa_calendar": [
{
"drug": "Donanemab",
"indication": "Early symptomatic AD",
"pdufa_date": "2025-Q2",
"priority_review": true,
"sponsor": "Eli Lilly"
}
],
"query_summary": {
"agencies": [
"FDA",
"EMA"
],
"condition": "Alzheimer Disease",
"horizon": "18m"
}
},
"type": "json"
}
},
"schema": {
"$schema": "https://json-schema.org/draft/2020-12/schema",
"properties": {
"input": {
"additionalProperties": false,
"properties": {
"method": {
"enum": [
"GET",
"HEAD",
"DELETE"
],
"type": "string"
},
"queryParams": {
"properties": {
"agency": {
"type": "string"
},
"condition": {
"type": "string"
},
"horizon": {
"type": "string"
},
"lang": {
"type": "string"
}
},
"type": "object"
},
"type": {
"const": "http",
"type": "string"
}
},
"required": [
"type",
"method"
],
"type": "object"
},
"output": {
"properties": {
"example": {
"type": "object"
},
"type": {
"type": "string"
}
},
"required": [
"type"
],
"type": "object"
}
},
"required": [
"input"
],
"type": "object"
}
},
"builder-code": {
"info": {
"a": "bc_gxy6qn5p"
},
"schema": {
"$schema": "https://json-schema.org/draft/2020-12/schema",
"additionalProperties": false,
"properties": {
"a": {
"description": "App builder code",
"pattern": "^[a-z0-9_]{1,32}$",
"type": "string"
},
"s": {
"description": "Service builder codes",
"items": {
"pattern": "^[a-z0-9_]{1,32}$",
"type": "string"
},
"type": "array"
},
"w": {
"description": "Wallet builder code",
"pattern": "^[a-z0-9_]{1,32}$",
"type": "string"
}
},
"type": "object"
}
}
}Use it
curl
curl "https://clinicalintelpulse.theaslangroupllc.com/api/clinical/approval-outlook" # -> 402 Payment Required, accepts[] lists how to pay # retry with a PAYMENT-SIGNATURE (or PAYMENT header) once paid
JavaScript
const res = await fetch("https://clinicalintelpulse.theaslangroupllc.com/api/clinical/approval-outlook");
if (res.status === 402) {
const { accepts } = await res.json();
// pay one of accepts[] via an x402 client, then retry with the payment header
}Python
import httpx
res = httpx.get("https://clinicalintelpulse.theaslangroupllc.com/api/clinical/approval-outlook")
if res.status_code == 402:
accepts = res.json()["accepts"]
# pay one of accepts[] via an x402 client, then retry with the payment headerMachine-readable
Everything on this page is also available as clean JSON at /resources/4549.json, and this resource appears in /discovery/resources and /discovery/search.